In the Checkmate 040 trial, HCC patients not responding to Sorafenib were treated with the combination of Nivolumab and Ipilimumab, another CTLA-4 inhibitor, at three different dosages [15]. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.